<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00443092</url>
  </required_header>
  <id_info>
    <org_study_id>CP100M</org_study_id>
    <secondary_id>VA MIRB ID # 00981</secondary_id>
    <nct_id>NCT00443092</nct_id>
  </id_info>
  <brief_title>Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee</brief_title>
  <official_title>A Double Blind Cross-over Study of the Efficacy of a Proprietary Cherry Juice Blend in Osteoarthritis of the Knee.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CherryPharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CherryPharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this research study is to test the ability of a proprietary cherry
      juice blend to be helpful in the treatment of osteoarthritis (OA) of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine if the proprietary tart cherry juice blend improves the
      pain and function in persons with knee osteoarthritis. A secondary objective is to ascertain
      if the blend lowers serum uric acid.

      This is a prospective double blind, placebo controlled cross-over study.

      The study will be performed in the Philadelphia VA Medical Center 1 South Rheumatology Clinic
      with patients meeting ACR criteria for Kellgren grade 2-3 knee osteoarthritis and 4-9 pain
      severity on a VAS. Fifty patients will be studied with each having 5 visits. Subjects will
      take either the proprietary cherry blend or placebo for 6 weeks and then switch. WOMAC pain
      and function will be the primary outcome with acetaminophen use, walking time and serum uric
      acid as secondary outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Western Ontario McMaster Osteoarthritis Index (WOMAC) Scores to be taken at Visits 2-5.</measure>
    <time_frame>Visit 3 (week 6-7), Visit 5 (week 13-14)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine if there is a decrease in amount of non-prescription pain medication taken and/or improvement in score on a timed walking test (Visits 2,3,4,5).</measure>
    <time_frame>Visit 3 (week 6-7), Visit 5 (week 13-14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine if there is a decrease in serum uric acid levels. (Visits 1,3,5)</measure>
    <time_frame>Visit 3 (week 6-7), Visit 5 (week 13-14)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>proprietary tart cherry juice blend (8 oz., BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control juice (color matched kool aid blend),(8 oz., BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>proprietary cherry juice blend (food)</intervention_name>
    <description>2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control juice (kool aid blend)</intervention_name>
    <description>2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is capable of giving informed consent.

          -  Subject is over 18 years and less than 80 years

          -  Subject has mild to moderate osteoarthritis of the knee based on all of the following
             3:

               1. Meets clinical ACR criteria

               2. Kellgren score of 2-3 on a Standing Knee x-ray within previous 24 months

               3. VAS pain score of 4-9 at screening visit

        Exclusion Criteria:

          -  Rheumatoid arthritis or other systemic inflammatory condition

          -  Chronic pain syndrome (fibromyalgia)

          -  Corticosteroid medication in last 2 months, either intra-articular or oral

          -  Intra-articular injections of hyaluronic acid in last 9 months

          -  Pregnant women (weight gain might confound degree of knee pain)

          -  Diabetes

          -  Inability to discontinue prescription medication for arthritis

          -  Unstable medical conditions that would likely prevent the subject from completing the
             study

          -  Food allergies - cherries, apples
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. R Schumacher, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Philadelphia &amp; University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>BLAU LW. Cherry diet control for gout and arthritis. Tex Rep Biol Med. 1950;8(3):309-11.</citation>
    <PMID>14776685</PMID>
  </reference>
  <reference>
    <citation>Connolly DA, McHugh MP, Padilla-Zakour OI, Carlson L, Sayers SP. Efficacy of a tart cherry juice blend in preventing the symptoms of muscle damage. Br J Sports Med. 2006 Aug;40(8):679-83; discussion 683. Epub 2006 Jun 21.</citation>
    <PMID>16790484</PMID>
  </reference>
  <reference>
    <citation>Seeram NP, Momin RA, Nair MG, Bourquin LD. Cyclooxygenase inhibitory and antioxidant cyanidin glycosides in cherries and berries. Phytomedicine. 2001 Sep;8(5):362-9.</citation>
    <PMID>11695879</PMID>
  </reference>
  <reference>
    <citation>He YH, Zhou J, Wang YS, Xiao C, Tong Y, Tang JC, Chan AS, Lu AP. Anti-inflammatory and anti-oxidative effects of cherries on Freund's adjuvant-induced arthritis in rats. Scand J Rheumatol. 2006 Sep-Oct;35(5):356-8.</citation>
    <PMID>17062434</PMID>
  </reference>
  <reference>
    <citation>Jacob RA, Spinozzi GM, Simon VA, Kelley DS, Prior RL, Hess-Pierce B, Kader AA. Consumption of cherries lowers plasma urate in healthy women. J Nutr. 2003 Jun;133(6):1826-9.</citation>
    <PMID>12771324</PMID>
  </reference>
  <reference>
    <citation>Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, Wolfe F, Gibofsky A, Simon L, Zlotnick S, Fort JG. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004 Aug;63(8):931-9. Epub 2004 Apr 13.</citation>
    <PMID>15082468</PMID>
  </reference>
  <reference>
    <citation>Johanson NA, Liang MH, Daltroy L, Rudicel S, Richmond J. American Academy of Orthopaedic Surgeons lower limb outcomes assessment instruments. Reliability, validity, and sensitivity to change. J Bone Joint Surg Am. 2004 May;86-A(5):902-9.</citation>
    <PMID>15118030</PMID>
  </reference>
  <reference>
    <citation>Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986 Aug;29(8):1039-49.</citation>
    <PMID>3741515</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2007</study_first_submitted>
  <study_first_submitted_qc>March 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2007</study_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2012</last_update_posted>
  <responsible_party>
    <name_title>Brian Ross</name_title>
    <organization>Cherry Pharm</organization>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>gout</keyword>
  <keyword>pain</keyword>
  <keyword>uric acid</keyword>
  <keyword>tart cherry</keyword>
  <keyword>alternative medicine</keyword>
  <keyword>knees</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

